The effects of fenofibrate on inflammation and cardiovascular markers in patients with active rheumatoid arthritis: A pilot study

Rheumatology International

Volumn 33, Issue 12, 2013, Pages 3045-3048

  Shirinsky, Ivan ^a   Polovnikova, Oksana ^a   Kalinovskaya, Natalia ^a   Shirinsky, Valery ^a  

^a NONE

Author keywords

Arthritis; Fenofibrate; PPAR alpha; Rheumatoid

Indexed keywords

ADIPOCYTOKINE; AZATHIOPRINE; C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LIPID; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DAS28; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOTHELIAL PROGENITOR CELL; FEMALE; HUMAN; INFLAMMATION; LOW BACK PAIN; MALE; MORNING STIFFNESS; NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; YOUNG ADULT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; INTERLEUKIN-6; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; STEM CELLS;

EID: 84892365536     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-012-2613-z     Document Type: Article

References (13)

1. Pyper SR, Viswakarma N, Yu S, Reddy JK (2010) PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 8:e002
2. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N (2005) Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 23(3):323-330
3. Benameur T, Tual-Chalot S, Andriantsitohaina R, Martinez MC (2010) PPARalpha is essential for microparticle-induced differentiation of mouse bone marrow-derived endothelial progenitor cells and angiogenesis. PLoS One 5(8):e12392
4. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Lau CP, Lai WH, Wong LY, Lam KF, Lau CS, Tse HF (2010) Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification. J Rheumatol 37(3): 529-535. doi:10.3899/jrheum.090782
5. Redondo S, Hristov M, Gordillo-Moscoso AA, Ruiz E, Weber C, Tejerina T (2008) High-reproducible flow cytometric endothelial progenitor cell determination in human peripheral blood as CD34?/CD144?/CD3-lymphocyte sub-population. J Immunol Methods 335(1-2):21-27
6. Shirinsky IV, Shirinsky VS (2011) Targeting nuclear hormone receptors: PPARalpha agonists as potential disease-modifying drugs for rheumatoid arthritis. Int J Rheumatol 2011:937843. doi:10.1155/2011/937843
7. Wahl C, Liptay S, Adler G, Schmid RM (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101(5):1163-1174. doi:10.1172/JCI992
8. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393(6687):790-793
9. Belfort R, Berria R, Cornell J, Cusi K (2010) Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 95(2):829-836
10. Goto M (2010) A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol 20(3):238-243
11. Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A (2011) Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Jt Bone Spine 78(2):179-183. doi: 10.1016/j.jbspin.2010.07.016
12. Kapur NK, Ashen D, Blumenthal RS (2008) High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc Health Risk Manag 4(1):39-57
13. Semb AG, Kvien TK, Aastveit AH, Jungner I, Pedersen TR, Walldius G, Holme I (2010) Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann Rheum Dis 69(11):1996-2001